PSG Introduces Groundbreaking Gene Therapy Risk Management Tool

Pharmaceutical Strategies Group Launches Innovative Gene Therapy Solution

Pharmaceutical Strategies Group (PSG), an EPIC company, has rolled out an innovative solution on its exclusive Artemetrx integrated data platform, named Artemetrx GeneCQ. This cutting-edge platform aims to revolutionize how healthcare payers manage the complexities associated with cell and gene therapies.

Understanding GeneCQ and Its Capabilities

GeneCQ employs sophisticated algorithms to parse through vast amounts of clinical, demographic, diagnosis, and medication data, pinpointing individual risk levels among specific population groups. With the backing of Artemetrx's extensive insights and extensive claims records, GeneCQ provides actionable real-world analyses, crucial for anticipating the timing of treatment uptake and understanding patient demographics.

The anticipated spending in the United States on cell, gene, and RNA-based therapies is expected to grow dramatically in the coming years, potentially exceeding between $13 billion and $22 billion. GeneCQ stands ready to equip healthcare payers with crucial data-driven insights that accurately predict exposure to these costly therapies.

Transformative Impact on Healthcare Payers

According to Rebekah Gregg, Chief Operating Officer of PSG, the Artemetrx platform continuously evolves to meet the changing demands of its clients. “This latest enhancement is not just an upgrade; it is transformative for the market,” she indicated. She went on to emphasize that financial exposures related to gene therapies require intelligent solutions, which GeneCQ delivers.

A Comprehensive Overview of the GeneCQ Tool

GeneCQ capitalizes on medical and pharmacy claims data, analyzing this information through proprietary clinical and actuarial algorithms. This process generates detailed outputs that highlight exposure levels by therapy and disease, thereby quantifying financial risks. Delivered as part of the Artemetrx web-based SaaS platform, GeneCQ encompasses several core features designed to support healthcare payers:

• Exposure Analysis by Therapy, Line of Business (LOB), ASO Group, and Member
• A Stop-Loss Modeler for financial planning
• Longitudinal Member Profiles for thorough member tracking

Helping Clients Prepare for the Future

Beth Hebert-Silvia, Senior Vice President and Health Plans Practice Leader at PSG, remarked on the impending growth in gene therapies. “Our health plan clients recognize the evolving landscape and are eager for a solution to mitigate their financial risk tailored to their unique member populations,” she stated. She added that with the robust capabilities of GeneCQ, health plans can efficiently quantify their risks and target members more likely to undergo gene therapies, empowering them to enhance care management.

For those interested in how Artemetrx GeneCQ can transform their organization, the PSG team encourages healthcare payers to reach out for a demo and further insights.

About Pharmaceutical Strategies Group (PSG)

Pharmaceutical Strategies Group is dedicated to guiding clients through the complex maze of drug cost management. As a thorn-free independent consultant and strategic partner, PSG equips healthcare payers with industry-leading intelligence and technologies, leading to significant savings on drug costs annually. Their deep commitment ensures they remain at the forefront of pharmacy management strategies.

About Artemetrx

Artemetrx is a revolutionary SaaS platform created by Pharmaceutical Strategies Group, integrating pharmacy and medical claims data for effective specialty drug cost management. This innovative solution grants payers remarkable insights to address drug cost challenges and enhance patient outcomes. With Artemetrx, PSG continues to offer advanced drug management solutions that deliver actionable insights, ensuring paves the way for substantial financial and clinical benefits.

Frequently Asked Questions

What is GeneCQ by PSG?

GeneCQ is an innovative tool designed to analyze data related to gene therapies, helping healthcare payers manage financial risks associated with these treatments.

How does GeneCQ benefit healthcare payers?

GeneCQ provides data-driven insights that accurately predict high-cost gene therapy exposure, enabling payers to manage their finances effectively.

What technologies does GeneCQ utilize?

GeneCQ employs proprietary algorithms to analyze clinical and pharmacy claims data, resulting in comprehensive risk assessments for specific populations.

What other solutions does PSG offer?

PSG offers a range of services focused on drug cost management, including industry intelligence and technology solutions designed to maximize savings for healthcare payers.

How can I learn more about GeneCQ?

Interested parties can reach out to PSG for a demo to explore the capabilities and benefits of the GeneCQ platform in detail.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.